Date: 03 Mar 2016
The prevalence of, and mortality from, colorectal cancer is increasing worldwide, and new strategies for prevention are needed to reduce the burden of this disease. The oral diabetes medicine metformin might have chemopreventive effects against cancer, including colorectal cancer. However, no clinical trial data exist for the use of metformin for colorectal cancer chemoprevention. Therefore, we devised a 1-year clinical trial to assess the safety and chemopreventive effects of metformin on sporadic colorectal cancer (assessed by adenoma and polyp recurrence) in patients with a high risk of adenoma recurrence.
For inquiries regarding this press release
E-mail: firstname.lastname@example.org Phone: +81 45 787 2640
Department of Gastroenterology and Hepatology,
Yokohama City University Graduate School of Medicine
Fukuura 3-9, Kanazawa-ku, Yokohama, Japan 236-0004